AVPR2 and nonpapillary renal cell carcinoma: The V2R antagonists Tolvaptan and OPC31260 can silence V2R and have been shown to reduce wound closure and cell viability of the 786-O and Caki-1 human clear cell RCC (ccRCC) cell lines.